Adeno-associated virus (AAV) has shown great potential as a delivery vector for therapeutic genes and is becoming a tool of choice for many emerging gene therapies. As more and more excellent clinical outcomes are being reported, the current potential of viral vectors in the clinic is limited due to manufacturing challenges including the absence of an efficient and scalable platform purification process. Affinity chromatography has proven to be a viable solution for the purification of viral vectors but to date, a small number o mostly single serotype-targeted affinity resins exist.
Download this whitepaper to learn how affinity chromatography can:
Technology Networks Limited
Woodview | Bull Lane Industrial Estate | Sudbury | C010 0FD | UK
Email: privacy@technologynetworks.com
© 2021 Technology Networks. All rights reserved
Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy